Moderna Q3 revenue rises to $1.9 billion and net income turns to $13 million
Moderna reported third-quarter 2024 total revenue of $1.9 billion, up from $1.8 billion a year earlier, and GAAP net income of $13 million, compared with a net loss of $3.6 billion in the prior-year quarter. The company reiterated its 2024 net product sales outlook of $3.0 to $3.5 billion, but cut its full-year research and development expense forecast and raised its capital expenditure estimate, which shareholders will weigh against the lower cash balance.
Key points
- Q3 2024 total revenue was $1.9 billion, versus $1.8 billion in Q3 2023; GAAP EPS was $0.03 versus a loss of $9.53 per share.
- Full-year 2024 R&D expense is now expected at $4.6 to $4.7 billion, down from a previous $4.8 billion.
- Full-year 2024 capital expenditures are now expected at about $1.2 billion, up from about $0.9 billion, including about $0.4 billion for the Norwood, MA campus.
- Cash, cash equivalents and investments were $9.2 billion at September 30, 2024, down from $10.8 billion at June 30, 2024.
The filing
Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 07, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.